Cargando…
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
BACKGROUND: A systematic review and meta-analysis was conducted to assess breast cancer (BC) outcomes among patients with early-stage hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) BC, receiving adjuvant endocrine therapy. METHODS: Randomized controlled tr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089079/ https://www.ncbi.nlm.nih.gov/pubmed/33677313 http://dx.doi.org/10.1016/j.breast.2021.02.009 |
_version_ | 1783686966742614016 |
---|---|
author | Salvo, Elizabeth M. Ramirez, Abril Oliva Cueto, Jenilee Law, Ernest H. Situ, Aaron Cameron, Chris Samjoo, Imtiaz A. |
author_facet | Salvo, Elizabeth M. Ramirez, Abril Oliva Cueto, Jenilee Law, Ernest H. Situ, Aaron Cameron, Chris Samjoo, Imtiaz A. |
author_sort | Salvo, Elizabeth M. |
collection | PubMed |
description | BACKGROUND: A systematic review and meta-analysis was conducted to assess breast cancer (BC) outcomes among patients with early-stage hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) BC, receiving adjuvant endocrine therapy. METHODS: Randomized controlled trials (RCTs) and real-world evidence (RWE) studies were identified using Ovid MEDLINE®, Embase, and Evidence-Based Medicine Reviews. Clinical and methodological similarities including alignment of outcome definitions with standardized definitions for efficacy endpoints criteria were assessed to evaluate feasibility of conducting a meta-analysis. Where feasible, 5-year probabilities of BC recurrence or death were estimated using a Bayesian hierarchical arm-based model. RESULTS: Of 21 included studies, 8 RCTs and 4 RWE studies reported outcome data of interest. There was heterogeneity in outcome reporting, as well as variation in recurrence risk amongst studies with aligned reporting. Of the 12 studies, 10 were considered for inclusion in a meta-analysis of BC recurrence or death. Only a subgroup analysis of node-positive patients (3 studies; n = 7307) was deemed feasible. The 5-year probability of BC recurrence or death was 17.2% (95% credible interval: 14.6%–20.3%). CONCLUSION: Although studies reporting recurrence outcomes were limited, there remains a high risk of BC recurrence, especially among node-positive patients. Approximately 1 in 6 women with node-positive HR+/HER2- early-stage BC receiving endocrine therapy experience recurrence or death within 5-years of initiating treatment, suggesting a need for novel treatments for this population. |
format | Online Article Text |
id | pubmed-8089079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-80890792021-05-13 Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis Salvo, Elizabeth M. Ramirez, Abril Oliva Cueto, Jenilee Law, Ernest H. Situ, Aaron Cameron, Chris Samjoo, Imtiaz A. Breast Original Article BACKGROUND: A systematic review and meta-analysis was conducted to assess breast cancer (BC) outcomes among patients with early-stage hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) BC, receiving adjuvant endocrine therapy. METHODS: Randomized controlled trials (RCTs) and real-world evidence (RWE) studies were identified using Ovid MEDLINE®, Embase, and Evidence-Based Medicine Reviews. Clinical and methodological similarities including alignment of outcome definitions with standardized definitions for efficacy endpoints criteria were assessed to evaluate feasibility of conducting a meta-analysis. Where feasible, 5-year probabilities of BC recurrence or death were estimated using a Bayesian hierarchical arm-based model. RESULTS: Of 21 included studies, 8 RCTs and 4 RWE studies reported outcome data of interest. There was heterogeneity in outcome reporting, as well as variation in recurrence risk amongst studies with aligned reporting. Of the 12 studies, 10 were considered for inclusion in a meta-analysis of BC recurrence or death. Only a subgroup analysis of node-positive patients (3 studies; n = 7307) was deemed feasible. The 5-year probability of BC recurrence or death was 17.2% (95% credible interval: 14.6%–20.3%). CONCLUSION: Although studies reporting recurrence outcomes were limited, there remains a high risk of BC recurrence, especially among node-positive patients. Approximately 1 in 6 women with node-positive HR+/HER2- early-stage BC receiving endocrine therapy experience recurrence or death within 5-years of initiating treatment, suggesting a need for novel treatments for this population. Elsevier 2021-02-20 /pmc/articles/PMC8089079/ /pubmed/33677313 http://dx.doi.org/10.1016/j.breast.2021.02.009 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Salvo, Elizabeth M. Ramirez, Abril Oliva Cueto, Jenilee Law, Ernest H. Situ, Aaron Cameron, Chris Samjoo, Imtiaz A. Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis |
title | Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis |
title_full | Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis |
title_fullStr | Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis |
title_full_unstemmed | Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis |
title_short | Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis |
title_sort | risk of recurrence among patients with hr-positive, her2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089079/ https://www.ncbi.nlm.nih.gov/pubmed/33677313 http://dx.doi.org/10.1016/j.breast.2021.02.009 |
work_keys_str_mv | AT salvoelizabethm riskofrecurrenceamongpatientswithhrpositiveher2negativeearlybreastcancerreceivingadjuvantendocrinetherapyasystematicreviewandmetaanalysis AT ramirezabriloliva riskofrecurrenceamongpatientswithhrpositiveher2negativeearlybreastcancerreceivingadjuvantendocrinetherapyasystematicreviewandmetaanalysis AT cuetojenilee riskofrecurrenceamongpatientswithhrpositiveher2negativeearlybreastcancerreceivingadjuvantendocrinetherapyasystematicreviewandmetaanalysis AT lawernesth riskofrecurrenceamongpatientswithhrpositiveher2negativeearlybreastcancerreceivingadjuvantendocrinetherapyasystematicreviewandmetaanalysis AT situaaron riskofrecurrenceamongpatientswithhrpositiveher2negativeearlybreastcancerreceivingadjuvantendocrinetherapyasystematicreviewandmetaanalysis AT cameronchris riskofrecurrenceamongpatientswithhrpositiveher2negativeearlybreastcancerreceivingadjuvantendocrinetherapyasystematicreviewandmetaanalysis AT samjooimtiaza riskofrecurrenceamongpatientswithhrpositiveher2negativeearlybreastcancerreceivingadjuvantendocrinetherapyasystematicreviewandmetaanalysis |